Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Muvalaplin (LY3473329) | Lp (a) Inhibitor | MedChemExpress
Muvalaplin and HRS-5346 Patent Filings in Asia | Shu-Yi Lin posted on ...
Muvalaplin | Inhibitor | TargetMol
muvalaplin
Muvalaplin | Drug Information, Uses, Side Effects, Chemistry ...
Muvalaplin (LY3473329) | Lipoprotein (a) inhibitor | Probechem Biochemicals
MUVALAPLIN
Muvalaplin tetrahydrochloride | TargetMol
Muvalaplin | C42H54N4O6 | CID 155369486 - PubChem
Muvalaplin Shows Promise in Lowering LP (A) Levels in Clinical TR | PDF ...
Lp(α)小分子抑制剂- Muvalaplin (1) | 化学空间 Chem-Station
Muvalaplin | 莫伐倍林 | TargetMol
Oral Muvalaplin effectively lowers lipoprotein (a) with no serious ...
Oral Muvalaplin for Lowering of Lipoprotein(a): A Randomized Clinical ...
Investigational Oral Agent Muvalaplin Reduces Lp(a) by Up to 85% in ...
Practical Fragments: Multivalent fragments in the clinic: Muvalaplin
Muvalaplin Significantly Lowers Lipoprotein(a) in Adults With High Risk ...
Can muvalaplin achieve safe and tolerable plasma concentrations ...
Update on lipid lowering therapies: Muvalaplin - Lp(a) Forum
Assessing the clinical progress of muvalaplin for reducing lipoprotein ...
Muvalaplin in Phase II angekommen | PZ – Pharmazeutische Zeitung
Phase 2 Data Support Muvalaplin for Lowering Lp(a), with Stephen ...
Mupirocin A Topical Antibiotic With A Unique Structure And Mechanism Of ...
Assessing the Impact of Muvalaplin on Major Cardiovascular Events in ...
上海Muvalaplin片III期临床试验-一项在脂蛋白(a)水平升高的成人中评价 Muvalaplin 对主要不良心血管事件影响的研究 ...
AHA: Muvalaplin Reduces Lipoprotein(a) Levels in Individuals With ...
Muvalaplin and Olpasiran Show Promise in Lowering Lp(a)
Landmark – First data with muvalaplin | R3I
Muvalaplin : nouvel inhibiteur de la lp(a) par voie orale
Muvalaplin as an Inhibitor of Lipoprotein(a) Formation | Metabolic ...
Muvalaplin|LY3473329——药研档案
Muvalaplin(LY3473329) | CAS 2565656-70-2 | Selleck
上海凌凯科技股份有限公司
#muvalaplin #ly3473329 #lp #lipoprotein #pelacarsen #olpasiran… | Min W.
#medicinalchemistry #drugdiscovery #drugdevelopment # ...
ChemGood
Measuring Lp(a) particles with a novel isoform-insensitive immunoassay ...
Nature里程碑：礼来揭秘首款降低Lp(a)水平小分子药物，已进入II期临床医药新闻-ByDrug-一站式医药资源共享中心-医药魔方
Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a ...
Genetics and Pathophysiological Mechanisms of Lipoprotein(a)‐Associated ...
Slides - Lp(a) Forum
穆伐普林(Muvalaplin) - 药物靶点：Lp(a)_在研适应症：外周动脉疾病，动脉粥样硬化，冠状动脉疾病_专利_临床_研发
Makisey｜note
科研助攻 | “隐形杀手“-- 血脂异常：有哪些干预靶点？ | MedChemExpress (MCE)_olpasiran-CSDN博客
JAMA：世界首个口服药，心脏病标志物水平降低65%-MedSci.cn
What Is Alp A Marker Of at Paige Hauslaib blog
Pelacarsen,Olpasiran,Muvalaplin) - 2024年12月 - 行业研究数据 - 小牛行研
Muvalaplin- World first drug to target previously untreatable life ...
KRAKEN Trial Highlights Muvalaplin’s Efficacy, Safety in Reducing ...
ランダムトライアル：Muvalaplin, Lp(a) 経口小分子Lp(a) 合成阻害剤｜Makisey
Lp(a)
2期临床礼来口服小分子药物Muvalaplin降脂蛋白（a）达85%——药研快讯
Muvalaplin, a small-molecule lipoprotein(a) inhibitor, produced ...
临床研究|口服Muvalaplin可将脂蛋白(a)降低多达86% - 知乎
穆伐普林(Muvalaplin) - 药物靶点：Lp(a)_在研适应症：外周动脉疾病，动脉粥样硬化_专利_临床_研发
ESC 365 - Muvalaplin, a Potent Small Molecule Inhibitor of Lipoprotein(a)
The Lp(a) Forum: Lipoprotein(a) Education and Research - Lp(a) Forum
Vector Skeletal formula of Mupirocin. Drug chemical molecule. 6473086 ...
#ESCCongress2023. Primul tratament oral care determină reducerea ...
Mupirocin molecule. It is antibacterial ointment used to treat impetigo ...
Design and Synthesis of Pleuromutilin Derivatives as Antibacterial ...
What Is Lp A? : Lipoprotein-a – VULCG
首个口服药物Muvalaplin降低遗传性高胆固醇超过50% | 香港致泰药业
1 INTRODUCTION in: Basic Concepts in Medicinal Chemistry
